Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00364676 | Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease | PHASE1 | COMPLETED | 67 | — | — | Jul 1, 2006 | Aug 1, 2015 | Sep 22, 2015 | 3 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Patients are dosed on Day 1 and Day 8 of a 21-day cycle. |
| 2 | EXPERIMENTAL | Patients are dosed on Day 1 of a 21-day cycle. |
| Name | Type | Description |
|---|---|---|
| VLI | DRUG | Patients are dosed on Day 1 and Day 8 of a 21-day cycle. |
Inclusion Criteria: 1. Histologically confirmed solid tumor refractory to standard therapy or for which no standard therapy is known to exist, or relapsed and/or refractory non-Hodgkin's lymphoma or Hodgkin's disease 2. Adequate hematologic, hepatic and renal functions as defined by laboratory test...